On the basis of these evidences, in a breast cancer setting it is becoming important to discriminate ERα-positive and ERα-negative tumors to specifically assess the best therapeutic approaches designed to impact adiponectin functions [64]. The gene discussed is ESR1; the disease is breast cancer.